论文部分内容阅读
将患者随机分为对照组及试验组各50例。试验组服用阿仑膦酸钠+钙尔奇D;对照组单服用钙尔奇D,12月后随访同部位骨密度,观察治疗后疗效,比较血糖控制达标及未达标者骨密度值差别。结果:试验组治疗前后骨密度值有显著性差异,对照组治疗前后无显著性差异。血糖达标组骨密度增幅较血糖未达标组高,有显著性差异。结论:阿仑膦酸钠治疗糖尿病性骨质疏松症有效,明显增加患者髋部骨密度值,予以药物干预同时,血糖持续控制良好患者的BMD增值幅度较之未良好控制患者大。
The patients were randomly divided into control group and test group of 50 cases. The experimental group was treated with alendronate + Caerchl D; the control group was given Caerchl D alone. After 12 months follow-up with the same site of bone mineral density, the curative effect after treatment was observed, and the differences of blood glucose control standard and non-standard bone mineral density were compared. Results: There was significant difference in BMD before and after treatment in the experimental group, but there was no significant difference in the control group before and after treatment. Blood glucose reached the standard group increased bone mineral density than the blood glucose did not reach the high group, a significant difference. CONCLUSION: Alendronate is effective in treating diabetic osteoporosis, significantly increasing the hip BMD in patients with drug intervention, meanwhile, the patients with well-controlled blood glucose control had better BMD appreciation than patients without good control.